Eton Pharmaceuticals (ETON) Other Non-Current Liabilities (2017 - 2025)
Eton Pharmaceuticals' (ETON) quarterly Other Non-Current Liabilities came in at $5.2 million in Q4 2025, up 186.39% year-on-year from $1.8 million in Q4 2024, and up 32.95% quarter-over-quarter from $3.9 million in Q3 2025.
Eton Pharmaceuticals (ETON) Other Non-Current Liabilities (2017 - 2025) Analysis & Trends
Eton Pharmaceuticals has disclosed Other Non-Current Liabilities across 4 years of filings, most recently posting $5.2 million for Q4 2025.
- Other Non-Current Liabilities for Q4 2025 came in at $5.2 million, up 186.39% year-over-year; the trailing twelve-month figure through Dec 2025 was $5.2 million (up 186.39% YoY), and the FY2025 annual result was $5.2 million, up 186.39% from the prior year.
- Other Non-Current Liabilities came in at $5.2 million for Q4 2025 at Eton Pharmaceuticals, up from $3.9 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $5.2 million in Q4 2025 to a low of $1.8 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Eton Pharmaceuticals | 820.42 Mn | 794.48 Mn | 13.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.24 Mn |
| Sep 30, 2025 | 3.94 Mn |
| Jun 30, 2025 | 4.27 Mn |
| Mar 31, 2025 | 4.15 Mn |
| Dec 31, 2024 | 1.83 Mn |
| Sep 30, 2018 | 1.58 Mn |
| Dec 31, 2017 | 520,000.00 |